CervoMed Earnings Call Transcripts
Fiscal Year 2026
-
Significant progress was reported in developing a targeted therapy for DLB, with strong phase II results and a de-risked phase III trial set to launch by year-end. Biomarker-driven patient selection and updated manufacturing processes are expected to enhance efficacy and market potential.
Fiscal Year 2025
-
Neflamapimod is advancing to phase 3 for pure DLB, targeting a large unmet need with strong phase 2 data showing significant clinical and biomarker improvements. The upcoming 24-week trial will enroll about 300 patients, with FDA feedback expected soon.
-
A novel therapy for pure DLB patients showed significant clinical and biomarker improvements in phase 2 trials, with plans for a pivotal phase III study. The company expects FDA feedback in Q4 and will seek $50–75 million in funding for the next trial phase.
-
Sustained 32-week data from the phase IIb trial show neflamapimod significantly slows DLB progression and reduces neurodegeneration biomarkers, especially in patients without Alzheimer's co-pathology. Plans are underway for a phase III trial using the 40 mg TID dose and CDR-SB as the primary endpoint.
-
Neflamapimod, an oral drug for DLB, showed significant clinical benefits in phase IIb trials, reducing disease progression by over 50% and supporting a strong case for a single pivotal phase III trial. The DLB market is large and underserved, with high pricing potential and flexible commercialization strategies.
Fiscal Year 2024
-
A late-stage biotech is advancing an oral therapy for Dementia with Lewy Bodies, with a pivotal phase II-B trial data readout imminent. The program targets early-stage patients using a biomarker-driven approach, supported by strong prior data and industry recognition.
-
Neflamapimod, an oral CNS drug, is advancing as the leading candidate for early-stage dementia with Lewy bodies, showing promising clinical and biomarker results. The pivotal phase IIb Rewind-LB study will report top-line data in December, potentially transforming DLB treatment.
-
Significant financial and clinical milestones were achieved, including a $50 million PIPE and completion of phase IIb trial enrollment, with top-line data expected in December. Strong scientific consensus supports the drug’s mechanism in DLB, and robust IP protection is in place.
-
Neflamapimod is being advanced for early-stage DLB, targeting patients with pure cholinergic deficits and using biomarkers like p-tau181 and GFAP for selection and monitoring. The phase II-B REWIND-LB trial is designed for high efficacy, with plans for a phase III trial in 2025, leveraging strong scientific rationale and recent CNS market trends.